Searchable abstracts of presentations at key conferences in endocrinology

ea0029p527 | Diabetes | ICEECE2012

Diabetes risk in relation to weight loss, weight stability and degree of obesity - The Swedish Obese Subjects (SOS) study

Peltonen M. , Sjostrom L. , Carlsson L.

Objective: Among severely obese individuals, surgically induced weight loss reduces the risk for type 2 diabetes. The aim of this study was to analyse the incidence and remission of type 2 diabetes among individuals with different degrees of obesity losing weight, and compare them with obese individuals remaining weight stable during follow-up.Research design and methods: The ongoing non-randomized prospective controlled Swedish Obese Subjects (SOS) inte...

ea0029oc3.2 | Diabetes Clinical | ICEECE2012

Weight-loss independent metabolic benefits of gastric bypass surgery? Experiences from the Swedish obese subjects (SOS) study

Peltonen M. , Sjostrom E. , Sjoholm K. , Carlsson L.

Objective: Bariatric surgery has a marked effect on diabetes risk in the obese. The aim of this study was to evaluate weight-loss independent effects of gastric bypass on glucose and insulin levels over 10-years of follow-up.Research design and methods: A total of 2010 obese individuals received bariatric surgery in the Swedish Obese Subjects (SOS) study (376 patients underwent non-adjustable or adjustable banding, 1369 underwent vertical banded gastropl...

ea0037oc6.2 | Thyroid | ECE2015

Biological activity of novel thyroid hormone analogues: role of Na+ taurocholate cotransporting polypeptide in liver selectivity

Brigante Giulia , Carlsson Bo , Kersseboom Simone , Peeters Robin P , Visser Theo J

Background: The interest in the potential effect of thyromimetics in lowering serum cholesterol is growing. Thyroid hormone actions on lipid metabolism are exerted in the liver and mediated by the T3 receptor TRβ1. The creation of molecules transported into hepatocytes by liver-specific transporters can increase the liver selectivity of thyromimetics. Sodium taurocholate co-transporting polypeptide (NTCP), a solute carrier protein primarily expressed on the basolateral me...

ea0011p832 | Thyroid | ECE2006

Insulin-like growth factor-1 counteracts 131I-induced thyroid stunning by stimulating the transcription of the sodium/iodide symporter (NIS)

Nordén M , Johanson C , Tedelind S , Larsson F , Carlsson T , Nilsson M

Thyroid stunning means reduced radioiodine uptake in thyroid tissue or tumour following a diagnostic 131I test dose. This may compromise subsequent 131I radiotherapy. Recently, we found that 131I inhibits iodide uptake in cultured thyroid cells at non-lethal absorbed doses. Here, we have investigated whether 131I irradiation affects the TSH-stimulated transcription of the sodium/iodide symporter (NIS) gene, and whether insulin-like g...

ea0047oc48 | Innovative Theranostics | Theranostics2016

Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors

Velikyan Irina , Wennborg Anders , Frldwisch Joachim , Olofsson Helena , Sandberg Dan , Lubberink Mark , Sandstrom Mattias , Lindman Henrik , Carlsson Jorgen , Sorensen Jens

The currently best known example of a commercialized theranostics is the combination of HercepTest and Herceptin wherein the former is used for HER2 expression assessment and selection of patients that might benefit from the treatment with the latter. However, HercepTest requires biopsy which is an invasive procedure, not sufficiently accurate, and very difficult to perform on several lesions and repeatedly in order to monitor the treatment response. While positron emission to...

ea0032p625 | Growth hormome IGF axis – basic | ECE2013

SNPs within the GH signaling pathway are associated with the fast, but not the long term, IGF1 response to GH replacement therapy in GH deficient adults

Glad Camilla , de Jesus Litenski Barbosa Edna , Filipsson Nystrom Helena , Carlsson Ekander Lena , Nilsson Staffan , Nilsson Anna , Svensson Per-Arne , Johannsson Gudmundur

Introduction: GH deficiency (GHD) in adults is associated with low serum levels of insulin-like growth factor 1 (IGF1) and a deteriorated cardio-metabolic profile. GH replacement therapy (GHRT) increases serum IGF1, an important mediator of the treatment response and safety marker of dose titration. The interindividual variation in treatment response is large and most likely influenced by genetic factors.Aim: The aim of this study was to test the hypothe...